Safety and Pharmacokinetics of AIC263029 in Patients with BKV-Associated Nephropathy: A Single and Multiple Dose Study

The primary objective of this clinical trial is to evaluate the **safety** of AIC263029 when administered as a single dose or multiple doses in individuals with **BKV-associated nephropathy**. This is clinically relevant as it aims to ensure that the treatment does not pose undue risk to patients, which is crucial for its potential therapeutic use. Additionally, the study seeks to understand the pharmacokinetics of AIC263029, which involves investigating how the drug is absorbed, distributed, metabolized, and excreted in the human body. This information is vital for determining appropriate dosing regimens and ensuring effective and safe treatment outcomes.

The clinical trial involves participants diagnosed with **BKV-associated nephropathy**. The study population includes both male and female subjects, with an age range categorized as adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed by the sponsor. The trial aims to gather data from a diverse group of adults without focusing on any particular vulnerable group.

The clinical trial is designed to evaluate the safety and pharmacokinetics of the investigational product AIC263029 in individuals with **BKV-associated nephropathy**. This study is a Phase 1 trial, characterized by a **randomized**, **double-blind**, and **controlled** design, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is expected to commence on October 16, 2024, and conclude by November 13, 2025, with the total duration of participant involvement varying based on individual response and adherence to the protocol.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. Subsequent follow-up visits will be scheduled at regular intervals to monitor safety, collect pharmacokinetic data, and assess the therapeutic response. These visits will include clinical assessments, laboratory evaluations, and adverse event monitoring.

The end-of-study visit will mark the completion of the trial for each participant, during which final assessments will be conducted to ensure participant safety and gather concluding data. The expected length of participant involvement will depend on the dosing regimen and individual response, with provisions for early termination in cases of significant adverse events, non-compliance, or withdrawal of consent. The trial's design and procedures are structured to ensure rigorous evaluation of the investigational product's safety profile and its pharmacokinetic properties in the target population.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on October 16, 2024, with an estimated completion date of November 13, 2025. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a range of parameters such as **biomarker** levels or symptom improvement scores to gather initial efficacy data. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints throughout the trial duration. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected.